Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a company headquartered in Allschwil, Switzerland. The firm develops and commercializes pharmaceuticals. Jean-Paul Clozel is the current CEO, occupying that position since 2017.\nThe company says this about itself: Headquartered near Basel, Switzerland - a biotech-hub of Europe-Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of over 700 highly qualified specialists dedicated to realizing our ambitious targets, a fully functional research center, and a strong balance sheet – the ideal constellation to bringing R&D efforts to business success.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Zentiva ks specializes in the development, manufacture and marketing of generic pharmaceutical products. It offers generic drugs, over the counter medicines, dietary supplements, cosmetics and pharmaceutical substances. The company's products cover therapy areas of cardiovascular disease, pain, alimentary, genitourinary tract diseases, inflammations and central nervous system diseases including digestive problems. Zentiva was founded in 1989 and is headquartered in Prague, Czech Republic.

Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland.

Nippon Chemiphar Co., Ltd. engages in the healthcare business. It manufactures, sells, imports, and exports ethical pharmaceuticals and diagnostic agents. It operates through the Pharmaceuticals and Others segments. The Pharmaceuticals segment manufactures and sells prescription drugs. The Others segment includes safety testing consignment, healthcare, and real estate businesses. The company was founded by Akira Yamaguchi on June 16, 1950 and is headquartered in Tokyo, Japan.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Richter Gedeon Nyrt deals with pharmaceutical production, research and development, trade, and marketing.

NutraSweet brand sweetener was discovered in 1965 at G.D. Searle and Company by researcher James Schlatter. He was working on research with amino acids to develop a treatment for ulcers. When he licked his finger to pick up a piece of paper, Schlatter got the world's first taste of NutraSweet. His amino acid combination may not have cured ulcers, but it helped create a product that revolutionized the category of "sweetener" for individuals and food ingredient companies. Since its introduction in 1981, millions of people worldwide have enjoyed and continue to enjoy more than 5,000 products containing NutraSweet brand sweetener. As the world's premier sugar substitute, NutraSweet offers great taste and virtually no calories. With regulatory approvals in more than 100 countries on six continents, NutraSweet is the most widely recognized and tested sweetening ingredient in the world.

Part of Syros Pharmaceuticals, Inc., Tyme, Inc. is an American company located in Wilmington, DE, that provides research and development services focused on developing drug candidates for the treatment of cancer. Steve Hoffman is the CEO, in this role since 2013. Tyme Technologies, Inc., now a subsidiary of Syros Pharmaceuticals, Inc. acquired Tyme, Inc. on March 05, 2015.\nThe company says this about itself: Tyme Inc. is a clinical-stage bio technology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company��s therapeutic approach is designed to take advantage of a cancer cell��s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body��s natural immune system. Tyme��s lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and the Company is preparing to initiate an additional Phase II clinical trial in pancreatic cancer.

Part of Zhuzhou Qianjin Pharmaceutical Co., Ltd., Hunan Qianjin Xiangjiang Pharmaceutical Industry Co., Ltd. is a company headquartered in Zhuzhou, China, that operates pharmacy chains. On October 28, 2004 Hunan Qianjin Pharmacy Retail Chain Holding Co. Ltd. acquired Hunan Qianjin Xiangjiang Pharmaceutical Industry Co., Ltd. from Zhuzhou Qianjin Pharmaceutical Co., Ltd. for $1.09 million.

Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 26 countries, Ajinomoto Co. had net sales of JPY 1,197.3 billion (USD 15.1 billion) in fiscal 2011. The Ajinomoto Group Standards of Business Conduct (hereinafter the "Standards of Conduct") describe the conduct that every member of the Ajinomoto Group must understand and practice every day in order to implement the Ajinomoto Group Philosophy in accordance with the Ajinomoto Group Way. The Standards of Conduct also represent the commitments made to all stakeholders by Ajinomoto Group companies. Ajinomoto aim to be "a group of companies that contributes to human health globally" by continually creating unique value to benefit customers. To become a global group of food companies centered on the world's No. 1 seasoning business. To become a global group of aminoscience companies that contributes to humankind with the world's No. 1 amino acid technology. To become a group of health-promoting companies with a scientific approach to good taste and health.

UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with a revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's, and Crohn's diseases. The Company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system (CNS) disorders (including epilepsy), inflammatory disorders (including allergy), and oncology.

Fujisawa Pharmaceutical Co. Ltd. develops, manufactures and markets pharmaceuticals and medical products. The Group's principal activity is the manufacture and sale of pharmaceuticals, medical equipment and supplies, home care products, chemicals and animal health products. Pharmaceuticals (ethical drugs, OTC drugs, toilet goods) accounted for 91% of fiscal 2002 revenues and other operations (food additives, industrial chemicals, animal drugs, research and clinical reagents). It was founded in 1894 and was headquartered in Osaka, JP

Secura Bio is an integrated biopharmaceutical company committed to giving patients access to innovative therapies. Its a diagnosis of a serious illness can change life in an instant and finding treatment options is key. At Secura Bio, they see things differently. They develop and commercialize innovative medicines and life-changing products for the patients that need them most. Secura Bio was founded in 2019 and is headquartered in Las Vegas, NV, and has operations in the U.S. and offices in San Diego.

Part of Novartis AG, Biochemie GmbH is an Austrian company located in Kundl specializing in pharmaceutical preparations.

Lion Corp. engages in the manufacture and sale of dental and body care, laundry, household cleaners, pharmaceuticals, and health products. It operates through the following business segments: Consumer Products, Industrial Products, Overseas, and Other. The Consumer Products segment manufactures and sells daily necessities, over-the-counter drugs and function food. These include toothpaste, toothbrush, hand soap, antipyretic analgesic, eye drops, nutritional drink, laundry detergent, softener, and bleach. The Industrial Products segment provides chemical raw materials and business supplies. These include oil and fat activator, conductive carbon, and professional cleaning agent. The Overseas segment handles the operation of overseas subsidiaries that manufactures and sells daily commodities. The Other segment includes construction contracting, real estate management, transportation storage, and staffing. The company was founded by Tomijiro Kobayashi on October 30, 1891 and is headquartered in Tokyo, Japan.

GenChem & GenPharm (Changzhou) Co., Ltd. is a private company headquartered in China. The firm manufactures organic chemical products.

Jiangsu Xinrui Pharmaceutical Co., Ltd., established on 2012-03-29, Business scope includes valsartan,Rosuvastatin Calcium,4-fluorine-3-Phenoxybenzaldehyde,3,3-Dimethylbutyryl chloride,Anhydrous sodium sulfite,Crystalline Aluminum Trichloride,Sodium chloride,30Hydrochloric acid production and sales;2-cyano-4-Methylbiphenyl,2-cyano-4-Bromomethylbiphenyl,L-Valine methyl ester hydrochloride,N-[(2-Cyanobiphenyl-4-base)Methyl]-L-Valine methyl ester hydrochloride,N-[(2-Cyanobiphenyl-4-base)Methyl]-L-Valine methyl ester oxalate,Valsartan methyl ester, N-(Triphenylmethyl)-5-(4-Bromomethylbiphenyl-2-base)Tetrazolium,4-(1-hydroxyl-1-methyl ethyl)-2-Propyl-1H-imidazole-5-ethyl carboxylate,4-Chloromethyl-5-Methyl-1,3-Dioxole-2-ketone,Trityl olmesartan medoxomil,Olmesartan medoxomil,o-Nitrobenzaldehyde,m-Nitrobenzaldehyde,m-Hydroxybenzaldehyde,p-Nitrobenzaldehyde,p-nitrobenzyl alcohol,2-chlorobenzyl chloride,p-Cyprobenzyl chloride,o-Chlorobenzaldehyde,p-Chlorobenzaldehyde,o-toluic acid,p-toluic acid,Benzaldehyde,p-Chlorophenylacetonitrile,2,2-Dimethylbutyryl chloride,4,4-dimethyl biphenyl sales.Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that are restricted by the state to be operated by enterprises or prohibited from import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Nanjing Sequoia Biotechnology Co., Ltd., established on 2014-10-09, Business scope includes biotechnology,medical technology,cosmetic,Technology research and development of feed additives,technology transfer,Technical Consulting and Technical Services;cosmetic,Feed Additive Sales;Chemical product sales;Self-operated and agent import and export business of various commodities and technologies.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Piramal Enterprises Ltd. engages in the business of pharmaceuticals and provision of financial services. It operates through the following segments: Pharmaceuticals Manufacturing and Services, Financial Services, and Healthcare Insights and Analytics. The Pharmaceuticals Manufacturing and Services segment operates through the following divisions: Pharma Solutions, Critical Care, Consumer Products Services and Imaging. The Financial Services segment offers a complete suite of financial products to meet the diverse needs of its customers. The Healthcare Insights and Analytics segment provides indispensable insights to life sciences companies as well as healthcare providers and payers through a variety of high value-added data and analytics, research reports, and knowledge-based services. The company was founded on April 26, 1947 and is headquartered in Mumbai, India.